


In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please amend pending claims 35 and 36 as noted below.


1-13. (Canceled)

14. (Previously Presented) A pharmaceutical preparation comprising a CFTR expression regulator, wherein the CFTR expression regulator is a polysaccharide that is an LPS core moiety comprising





wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; wherein Y is selected from the group consisting of rhamnose and H; and wherein Z is selected from the group consisting of glucose and H; and a pharmaceutically acceptable carrier.

15. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises




16. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises







17. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises




18. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises




19. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises



20. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises




21. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.
22. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is sterile.
23. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated in a unit dosage in an amount effective for treating *Pseudomonas* infection.
24. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated as an aerosol for inhalation.
25. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated as an injectable preparation.
26. (Previously Presented) A composition of matter comprising
a covalent conjugate of a non-toxic lipid and a polysaccharide comprising




wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.


27. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




28. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




29. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




30. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises




31. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises



32. (Previously Presented) The composition of matter of claim 26 wherein the polysaccharide comprises






33. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

34. (Previously Presented) The composition of matter of claim 26 wherein the lipid has the following structural formula: $\text{CH}_3(\text{CH}_2)_n\text{COOH}$ wherein $n=1-50$.


35. (Currently amended) The composition of matter of claim 34 ~~wherein the lipid~~ wherein the lipid is in the wall of a liposome containing a bioactive agent, wherein the bioactive agent is selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule.

36. (Currently amended) A composition of matter comprising
a covalent conjugate of a bioactive agent wherein the bioactive agent is selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule, and a polysaccharide comprising




wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.

37. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises







38. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises




39. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises




40. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises





41. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises



42. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises





43. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

44-68. (Canceled)